Head-to-head · Cost-Efficiency Index
LunaRx vs Peptivo
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
LunaRx
Shoppers who value simple flat-rate pricing and a no-cost-if-declined guarantee over named clinical credentials.
Visit LunaRxPeptivo
Shoppers who value verifiable named pharmacy and medical-leadership credentials, willing to complete an intake quiz to see final pricing.
Visit PeptivoThe verdict
LunaRx and Peptivo tie on the Cost-Efficiency Index at 63/100, so neither wins outright on the numbers. For most shoppers we'd start with LunaRx (ranked #197, a hair above #199) — Shoppers who value simple flat-rate pricing and a no-cost-if-declined guarantee over named clinical credentials. But Peptivo is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs LunaRx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | LunaRx | Peptivo |
|---|---|---|
| Cost-Efficiency Index | 63/100 | 63/100 |
| Semaglutide / mo | $149/mo (compounded) | $169/mo (compounded) |
| Tirzepatide / mo | $199/mo (compounded) | $249/mo (compounded) |
| Semaglutide / yr (modeled) | $1,788 | $2,028 |
| Tirzepatide / yr (modeled) | $2,388 | $2,988 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #197 | #199 |
LunaRx
63/100Where the value is
- Advertises simple, flat-rate pricing with no hidden fees
- '$0 if not approved' removes financial risk from a declined consult
- Founder is publicly named (Anamaria Galvan, RN) rather than fully anonymous leadership
The tradeoffs
- No named physician medical director -- only an RN founder is identified
- No named compounding pharmacy partner
Peptivo
63/100Where the value is
- Four named, verifiable compounding pharmacy partners across multiple states
- Named Chief Medical Innovation Officer (MD) and VP of Pharmacy Operations, plus a physician advisory board
- Ships to all 50 states
The tradeoffs
- Exact GLP-1 pricing gated behind an intake quiz, not shown as a static table
- Company's own sibling NAD+ products use a first-month-then-higher pricing structure, raising unconfirmed suspicion the GLP-1 pricing may work the same way
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.